Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway
暂无分享,去创建一个
K. Kolibaba | F. Awan | Mitchell R. Smith | S. Mitra | J. Sharman | A. Shustov | C. Hagenstad | Danjie Zhang | C. Yasenchak | Esteban Abella-Dominicis